Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Frydenberg

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
European Urology Open Science|July 13, 2023
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate BiopsyBrian D Kelly, Gideon Ptasznik, Matthew J Roberts, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 11, 2021
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer OrganoidsNicholas Choo, Susanne Ramm, Jennii Luu, et al.
ANZ Journal of Surgery|March 3, 2021
Proposed delay for safe surgery after COVID-19Joshua G Kovoor, N Ann Scott, David R Tivey, et al.
Translational Andrology and Urology|November 16, 2023
<sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional studyWilliam Gondoputro, Paul Doan, Athos Katelaris, et al.
BMJ Open|March 3, 2021
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trialVisalini Nair-Shalliker, David P Smith, Val Gebski, et al.
BJU International|October 17, 2013
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer RegistrySue M Evans, Jeremy L Millar, Mark Frydenberg, et al.
International Journal of Cancer|June 15, 2019
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trialPatrick Bowden, Andrew W See, Mark Frydenberg, et al.
BJU International|October 5, 2017
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cellsLaura H Porter, Kohei Hashimoto, Mitchell G Lawrence, et al.
The Lancet. Oncology|May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
European Urology Open Science|January 13, 2022
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) ConsortiumJonathan Olivier, Weiyu Li, Daan Nieboer, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
European Urology Open Science|July 13, 2023
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate BiopsyBrian D Kelly, Gideon Ptasznik, Matthew J Roberts, et al.
SLAS Discovery : Advancing Life Sciences R & D|June 11, 2021
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer OrganoidsNicholas Choo, Susanne Ramm, Jennii Luu, et al.
ANZ Journal of Surgery|March 3, 2021
Proposed delay for safe surgery after COVID-19Joshua G Kovoor, N Ann Scott, David R Tivey, et al.
Translational Andrology and Urology|November 16, 2023
<sup>68</sup>Ga-PSMA-PET/CT in addition to mpMRI in men undergoing biopsy during active surveillance for low- to intermediate-risk prostate cancer: study protocol for a prospective cross-sectional studyWilliam Gondoputro, Paul Doan, Athos Katelaris, et al.
BMJ Open|March 3, 2021
High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trialVisalini Nair-Shalliker, David P Smith, Val Gebski, et al.
BJU International|October 17, 2013
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer RegistrySue M Evans, Jeremy L Millar, Mark Frydenberg, et al.
International Journal of Cancer|June 15, 2019
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trialPatrick Bowden, Andrew W See, Mark Frydenberg, et al.
BJU International|October 5, 2017
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cellsLaura H Porter, Kohei Hashimoto, Mitchell G Lawrence, et al.
The Lancet. Oncology|May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
European Urology Open Science|January 13, 2022
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) ConsortiumJonathan Olivier, Weiyu Li, Daan Nieboer, et al.
Pageof 19